Drug Search Results
More Filters [+]

Albinterferon alfa-2b

Alternative Names: albinterferon alfa-2b
Latest Update: 2011-01-06
Latest Update Note: Clinical Trial Update

Product Description

a novel fusion protein of human albumin and human IFNalpha-2b. Albinterferon alfa-2b exhibits high antiviral activity, and appears to offer safety/tolerability comparable to the current standard of care, and health-related quality-of-life benefits in patients with CHC (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19275518/)

Mechanisms of Action: IFNA Agonist

Novel Mechanism: Yes

Modality: Fusion Protein

Route of Administration: N/A

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Albinterferon alfa-2b

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Hepatitis B, Chronic|Hepatitis A|Hepatitis C, Chronic|Hepatitis C

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2008-002039-34

P2

Completed

Hepatitis C, Chronic

2010-12-03

CABF656A2206

P2

Terminated

Hepatitis B, Chronic|Hepatitis A

2010-11-01

ND

P2

Terminated

Hepatitis C

2009-12-11

Recent News Events

Date

Type

Title